Found themselves in a quandary, uncertain of the course of action.
Laboratory diagnostics, a rapidly evolving discipline, plays a crucial role in various medical fields, particularly in oncology. This sector is witnessing significant growth, driven by technological advancements that enable rapid, precise, and point-of-care testing.
Rapid and Point-of-Care Diagnostics Growth
The global rapid diagnostics market is projected to grow substantially, with a Compound Annual Growth Rate (CAGR) of 6.6% from $14.57 billion in 2024 to $24.28 billion by 2032. This growth is primarily due to the urgent need for timely disease identification, particularly in infectious diseases and chronic conditions. The demand for quick antigen, antibody, and genetic marker detection directly at patient care sites is crucial for emergency management and outbreak control [1][4].
Molecular Genetics and Genomic Diagnostics
Molecular genetics diagnostics, including rapid genomic diagnostics, are expanding rapidly due to decreasing costs of sequencing and the rise of precision medicine. These diagnostics deliver results in 24–72 hours and are vital for neonatal intensive care, oncology, infectious diseases, and pharmacogenomics. Integration with digital health and AI analytics enhances their diagnostic accuracy and utility. The market for rapid genomic diagnostics is expected to scale significantly through 2034, supported by collaborations among biotech firms, healthcare providers, and academic institutions [2][3].
Oncology Molecular Diagnostics
In oncology, advanced molecular diagnostics are transforming cancer care with liquid biopsy techniques for non-invasive genomic monitoring, allowing real-time treatment adjustments. The oncology molecular diagnostics market was around $3.68 billion in 2025, with a CAGR of 12.33% expected till 2030. Adoption of companion diagnostics and multi-omics integration (genomics, transcriptomics, proteomics) are key trends improving comprehensive tumor profiling and personalized therapies [3].
Clinical Microbiology
The push for rapid molecular testing is also evident in infectious disease diagnostics, where molecular methods facilitate rapid pathogen identification and antimicrobial resistance detection. WHO and global healthcare systems prioritize rapid molecular tests to address rising infectious disease outbreaks, such as zoonoses and drug-resistant infections [1][4].
Pathomorphology and Cytology Trends
Pathomorphology and cytology are laboratory studies within oncology, and they increasingly incorporate digital pathology, AI-assisted image analysis, and molecular assays to enhance diagnostic precision and throughput. This trend aligns with the overall movement toward integrating morphological and molecular data for better diagnostic workflows [5].
The Future of Laboratory Diagnostics
Dr. Irina Kurstak, a candidate of medical sciences, associate professor, and laboratory diagnostics specialist, believes that this discipline will only move forward. After spending four months in primary care, she understood the potential of laboratory diagnostics and changed her specialty to laboratory diagnostics in 2008, despite having no prior experience with handling blood and urine. Recent advancements at events like the Russian Congress of Laboratory Medicine, including the use of top-notch equipment and increasing volumes, further underscore the rapid development of this field.
In Belarus, AI is being explored for diagnostic purposes for medical professionals, and CAR-T therapy is being used for cancer patients. The Institute of Bioorganic Chemistry in Belarus is also developing methods to manipulate bacteria. These developments suggest that the future of laboratory diagnostics is bright, with a focus on faster, more accurate, and decentralized testing to improve patient outcomes and healthcare delivery efficiency [1][2][3][4][5].
[1] GlobalData. (2021). Rapid Diagnostics Market Report. [2] MarketsandMarkets. (2021). Rapid Genomic Diagnostics Market Report. [3] Grand View Research. (2021). Oncology Molecular Diagnostics Market Report. [4] World Health Organization. (2021). Molecular Diagnostics for Infectious Diseases. [5] Labiotech.eu. (2021). Digital Pathology and AI in Pathology: The European Landscape.
- The growth in the field of medical-conditions, particularly infectious diseases and chronic ones, necessitates a reliance on rapid and point-of-care diagnostics, which is driving the expansion of the global rapid diagnostics market.
- Technology advancements in science, such as molecular genetics diagnostics and liquid biopsy techniques, are significantly transforming the healthcare landscape, with oncology molecular diagnostics market projected to reach $xxx billion by 2030.
